The Navy says its highest-ranking military officer has been successfully treated for early-stage breast cancer ...
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
If you or a loved one have breast cancer, you are not alone. With support groups at local hospitals and the Susan G. Komen’s ...
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
At ESMO, Multiple Enhertu Studies Highlight Challenges of Selecting, Managing Breast Cancer Patients
Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.
The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback